repeat testing at progression of egfr nsclc
Published 4 years ago • 40 plays • Length 7:41Download video MP4
Download video MP3
Similar videos
-
3:31
osimertinib changed the treatment paradigm for repeat molecular testing at progression?
-
2:50
optimizing therapy at progression of egfr-mutant nsclc
-
58:24
time for even more precision in testing and treatment of egfr-mutated nsclc
-
2:21
treatment of egfr nsclc after progression
-
3:41
what is the rationale for repeat molecular testing at progression?
-
3:34
repeat biopsy in lung cancer patients with egfr mutation
-
41:23
multimodal management of early-stage nsclc: egfr-targeted therapy in perioperative settings
-
41:59
testing for common and uncommon egfr mutations to guide egfr-targeted therapy in nsclc
-
5:00
case 2: testing for egfr in lung adenocarcinoma
-
0:50
targeted option for non-small cell lung cancer #2023 #oncology #lungcancer
-
3:36
testing and recommendations: egfr-mutated stage iv nsclc
-
2:08
value of repeat mutation testing for alk nsclc
-
2:44
mutation testing at progression of alk-rearranged nsclc
-
9:30
egfr testing for nsclc
-
59:37
refining biomarker testing and targeted treatment of nsclc with egfr mutations
-
5:55
a case of egfr-mutant non–small cell lung cancer
-
1:05:12
new horizons in egfr-mutated nsclc: broadening the impact of precision testing
-
4:25
egfr tkis for relapsed/refractory nsclc_old2
-
1:32
real-world comparison assesses mobocertinib in nsclc with egfr exon 20